An interventional study of J-Valve TF System in Aortic Valve Disease, Aortic Valve Insufficiency and Aortic Regurgitation, sponsored by JC Medical, Inc., an affiliate of Edwards Lifesciences LLC. Active, not recruiting at 9 sites in United States. Per ClinicalTrials.gov, last updated 2025-07-11.
Sponsored by JC Medical, Inc., an affiliate of Edwards Lifesciences LLC (part of Edwards Lifesciences) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Aortic Valve Insufficiency by Edwards Lifesciences — 1 open to participants now, 4 under way, none of them phase 3. Aortic Valve Insufficiency · Edwards Lifesciences.
Among the 11 studies in Aortic Valve Insufficiency by Edwards Lifesciences, this one is the 10th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2023, is one of 10 with no phase, and was the 9th registered.
171 studies on the registry are indexed under Aortic Valve Insufficiency; 56 are open to participants now.
Browse Aortic Valve Insufficiency studies →1 of the 11 studies in Aortic Valve Insufficiency by Edwards Lifesciences is open now, in 2 countries. Recruiting first, the newest first:
Edwards Lifesciences · Sites in United States, Canada
By country, each count listing its studies:
Of the 39 Aortic Valve Insufficiency studies recruiting now, 31 (79%) set no upper age limit and 2 (5%) stop at 75 or younger; 4 take children under 18; 4 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 2 started in 2023.
This study's enrollment of 25 is below the median of 123 across 92 interventional studies indexed under Aortic Valve Insufficiency.
Median enrollment 164 across the 10 interventional studies. Of the 6 that completed or were terminated, 6 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under JC Medical, Inc., an affiliate of Edwards Lifesciences LLC, one of the names counted as Edwards Lifesciences. Under that name alone:
JC Medical, Inc., an affiliate of Edwards Lifesciences LLC is the lead sponsor of 3 studies on the registry; none are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Aortic Valve Insufficiency by Edwards Lifesciences, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main objective of this study is to assess the preliminary safety and effectiveness of the J-Valve TF System in patients with symptomatic severe native aortic regurgitation who are judged by a multi-disciplinary heart team to be eligible for the device and to be at high risk for open surgical aortic valve replacement.
The EFS is a prospective, single arm, multi-center, interventional study that will enroll up to 25 subjects in up to 15 centers in the United States and/or Canada and report the primary endpoint of all-cause death or disabling stroke at 30 days.
171 studies on the registry are indexed under Aortic Valve Insufficiency; 56 are open to participants now.
This study's enrollment of 25 is below the median of 123 across 92 interventional studies indexed under Aortic Valve Insufficiency.
Browse Aortic Valve Insufficiency studies →JC Medical, Inc., an affiliate of Edwards Lifesciences LLC is the lead sponsor of 3 studies on the registry; none are open to participants now.
First submitted before JC Medical, Inc. became part of Edwards Lifesciences.
Compared within Aortic Valve Insufficiency, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Aortic Valve Disease. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Anatomic Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: J-Valve TF System
The J-Valve TF System is a transcatheter aortic valve replacement system that consists of the J-Valve TF Bioprosthesis, J-Valve TF Delivery Device, and Loading Accessories.
Number of patients that do not experience death or disabling stroke
Freedom from death or disabling stroke Disabling stroke is evaluated using a standardized scale
Time frame: 30 days after the valve procedure
Number of patients and procedures achieving technical success
Procedures achieving the following: * Patient is alive; * There was successful access, delivery of the valve, and retrieval of the delivery device; * There was correct positioning of a single prosthetic heart valve into the proper anatomical location; * There was no need for surgery or intervention due to the device, except permanent pacemaker placement, or for a major complication that it vascular, access-related, or cardiac in nature
Time frame: At point patient exits the procedure room
Number of patients and procedures achieving device success
* There was successful access, delivery of the valve, and retrieval of the delivery device; * There was correct positioning of a single prosthetic heart valve into the proper anatomical location; * There was no need for surgery or intervention due to the device, except permanent pacemaker placement, or for a major complication that it vascular, access-related, or cardiac in nature; * Patient is alive; * There was not surgery or intervention due to the device, except permanent pacemaker placement, or for a major complication that it vascular, access-related, or cardiac in nature; * The valve was performing as intended, measured by echocardiography
Time frame: 30 days after the valve procedure
Number of patients with a safety-related event outcome
Freedom from: * All-cause death; * All stroke; * Valve Academic Research Consortium (VARC)-3 type 2-4 bleeding; * Major vascular, access-related, or cardiac structural complication; * Acute kidney injury stage 3 or 4; * Moderate or severe aortic regurgitation; * New permanent pacemaker due to procedure related conduction abnormalities; * Surgery or intervention related to the device.
Time frame: 30 days after the valve procedure
Number of patients experiencing success
No re-hospitalization or re-interventions for the underlying condition and improvement, from baseline, in symptoms, which are measured using the Kansas City Cardiomyopathy Questionnaire (KCCQ) Overall Summary (OS) score. Success in an increase from baseline of 10 or more points on the KCCQ-OS score.
Time frame: 1 year after the valve procedure
Number of patients meeting clinical efficacy outcome at 2 years
* Freedom-from all-cause death; * Freedom from all stroke; * Freedom from hospitalization for procedure- or valve-related causes; * Freedom from KCCQ-OS score \< 45 or decline from baseline of \>10 points; * Good Outcome: Alive with change in KCCQ-OS score \>=10 points; * Excellent outcome: Alive with change in KCCQ-OS score \>=20 points.
Time frame: 2 years after the valve procedure
Number of patients meeting clinical efficacy outcome at 3 years
* Freedom-from all-cause death; * Freedom from all stroke; * Freedom from hospitalization for procedure- or valve-related causes; * Freedom from KCCQ-OS score \< 45 or decline from baseline of \>10 points; * Good Outcome: Alive with change in KCCQ-OS score \>=10 points; * Excellent outcome: Alive with change in KCCQ-OS score \>=20 points.
Time frame: 3 years after the valve procedure
Number of patients meeting clinical efficacy outcome at 4 years
* Freedom-from all-cause death; * Freedom from all stroke; * Freedom from hospitalization for procedure- or valve-related causes; * Freedom from KCCQ-OS score \< 45 or decline from baseline of \>10 points; * Good Outcome: Alive with change in KCCQ-OS score \>=10 points; * Excellent outcome: Alive with change in KCCQ-OS score \>=20 points.
Time frame: 4 years after the valve procedure
Number of patients meeting clinical efficacy outcome at 5 years
* Freedom-from all-cause death; * Freedom from all stroke; * Freedom from hospitalization for procedure- or valve-related causes; * Freedom from KCCQ-OS score \< 45 or decline from baseline of \>10 points; * Good Outcome: Alive with change in KCCQ-OS score \>=10 points; * Excellent outcome: Alive with change in KCCQ-OS score \>=20 points.
Time frame: 5 years after the valve procedure
Number of patients achieving long-term clinical efficacy for valve function
Freedom from: * Bioprosthetic valve failure (defined as Valve-related mortality or aortic valve re-operation/re-intervention or Stage 3 hemodynamic valve deterioration); * Stroke or peripheral embolism (presumably valve- related, after ruling out other non-valve etiologies); * VARC-3 Type 2-4 bleeding secondary to or exacerbated by antiplatelet * or anticoagulant agents, used specifically for valve- related concerns.
Time frame: 5 years after the valve procedure
Plan to share: No
Ran from Oct 2023 to primary completion in Jul 2024, 9 months.
Of 44 interventional studies with no phase under Aortic Valve Insufficiency, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 74. This study's 9 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.